IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease by Lorenz, Georg et al.
ORIGINAL RESEARCH
published: 01 October 2019
doi: 10.3389/fimmu.2019.02162
Frontiers in Immunology | www.frontiersin.org 1 October 2019 | Volume 10 | Article 2162
Edited by:
Christoph Thiemermann,




Queen Mary University of London,
United Kingdom
Massimo Collino,





This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology
Received: 25 June 2019
Accepted: 28 August 2019
Published: 01 October 2019
Citation:
Lorenz G, Moschovaki-Filippidou F,
Würf V, Metzger P, Steiger S, Batz F,
Carbajo-Lozoya J, Koziel J,
Schnurr M, Cohen CD,
Schmaderer C, Anders H-J,
Lindenmeyer M and Lech M (2019)
IFN Regulatory Factor 4 Controls
Post-ischemic Inflammation and
Prevents Chronic Kidney Disease.
Front. Immunol. 10:2162.
doi: 10.3389/fimmu.2019.02162
IFN Regulatory Factor 4 Controls
Post-ischemic Inflammation and
Prevents Chronic Kidney Disease
Georg Lorenz 1,2, Foteini Moschovaki-Filippidou 1, Vivian Würf 1, Philipp Metzger 3,
Stefanie Steiger 1, Falk Batz 1, Javier Carbajo-Lozoya 2, Joanna Koziel 4, Max Schnurr 3,
Clemens D. Cohen 1, Christoph Schmaderer 2, Hans-Joachim Anders 1,
Maja Lindenmeyer 1,5 and Maciej Lech 1*
1Department of Nephrology, Klinikum der Ludwig-Maximilians-Universität München, Medizinische Klinik und Poliklinik IV,
Munich, Germany, 2Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany,
3Division of Clinical Pharmacology, Department of Medicine IV, Center of Integrated Protein Science Munich (CIPSM),
Klinikum der Universität München, LMU Munich, Munich, Germany, 4Microbiology Department, Faculty of Biochemistry
Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, 5 III. Department of Medicine, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
Ischemia reperfusion injury (IRI) of the kidney results in interferon regulatory factor 4
(IRF4)–mediated counter-regulation of the acute inflammatory response. Beyond that,
IRF4 exerts important functions in controlling the cytokine milieu, T-cell differentiation,
and macrophage polarization. The latter has been implicated in tissue remodeling. It
therefore remains elusive what the role of IRF4 is in terms of long-term outcome following
IRI. We hypothesized that an inability to resolve chronic inflammation in Irf4−/− mice
would promote chronic kidney disease (CKD) progression. To evaluate the effects of
IRF4 in chronic upon acute injury in vivo, a mouse model of chronic injury following
acute IRI was employed. The expression of Irf4 increased within 10 days after IRI in renal
tissue. Both mRNA and protein levels remained high up to 5 weeks upon IRI, suggesting
a regulatory function in the chronic phase. Mice deficient in IRF4 display increased
tubular cell loss and defective clearance of infiltrating macrophages. These phenomena
were associated with increased expression of pro-inflammatory macrophage markers
together with reduced expression of alternatively activated macrophage markers. In
addition, IRF4-deficient mice showed defective development of alternatively activated
macrophages. Hints of a residual M1 macrophage signature were further observed in
human biopsy specimens of patients with hypertensive nephropathy vs. living donor
specimens. Thus, IRF4 restricts CKD progression and kidney fibrosis following IRI,
potentially by enabling M2 macrophage polarization and restricting a Th1 cytokine
response. Deteriorated alternative macrophage subpopulations in Irf4−/− mice provoke
chronic intrarenal inflammation, tubular epithelial cell loss, and renal fibrosis in the long
course after IRI in mice. The clinical significance of these finding for human CKD remains
uncertain at present and warrants further studies.
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INTRODUCTION
Renal ischemia reperfusion injury (IRI) refers to the damage
that occurs from interruption and the subsequent restoration
of blood flow to the kidney. Hypoxia that develops upon IRI
results in irreversible damage to tubular cells in the S3 segment
of the nephrons and an excessive innate immune response, i.e.,
necroinflammation (1). Duration of ischemia, the area exposed
to injury, immunologic factors, and genetic factors determine
the degree of irreversible nephron loss and subsequent scarring.
However, it is still not clear how to estimate the long-term
outcome in patients following acute kidney injury (AKI). Further,
the importance of some negative regulators of inflammation
remains not well-established with respect to long-term outcome
following chronic post-ischemic AKI. Long-term cohort studies
indicate that AKI is an underestimated yet significant risk factor
for chronic kidney disease (CKD) (2). Even with normal serum
creatinine following an episode of acute tubule necrosis, a true
“restitutio ad integrum” cannot be assumed (3, 4). Identification
of molecular and cellular mechanisms involved in the transition
from acute to chronic renal injury might constitute an important
step on the way to new therapeutic approaches.
Unlike other interferon regulatory factors (IRFs), expression
of IRF4 is not regulated by interferons, and it is mainly found in
immune cells (5–7). IRF4 orchestrates key regulatory functions
in adaptive immunity such as maturation of B and plasma cells
and Ig isotype switching. Moreover, IRF4 is essential for Th2
effector cell differentiation (8) and for the differentiation of Tregs
and their effector functions (9). The expression of IRF4 in the
Th2 subpopulation is higher than in Th1 or Th17 cells (10).
IRF4-deficient CD4+ T cells do not differentiate toward the
Th2 cell lineage or produce IL-4, IL-5, IL-13, and IL-21 upon
Th2 skewing conditions (11–14). Consequently, a lack of IRF4
results in enhanced IFN-γ production (12, 13). Moreover, IRF4
affects IL-10 expression, which is important for the macrophage-
mediated resolution of inflammation (15–17). IRF4 has already
been linked to macrophage polarization. Others have shown that
Jumonji domain containing-3 pathway, which regulates IRF4
expression, is essential for M2 macrophage polarization in mice
exposed to chitin or parasitic infection (18). IRF4 deficiency was
shown to result in decreased expression of the M2 phenotype’s
markers, such as Arg1, Ym1, and Fizz1 (18).
Our previous reports proved that IRF4-deficient mice
developed exaggerated intrarenal inflammation and tissue injury
upon renal injury, which required intrarenal phagocytes and
TNFα secretion (19). Thus, IRF4 acts as a negative regulator
of the acute inflammatory response upon IRI. Yet, to which
direction IRF4 dictates the fate of CKD thereafter remains not
well-defined. Given its roles in the pathogenesis of various
chronic inflammatory diseases from atherosclerosis to lupus
nephritis (LN) (20–22), its potent immunoregulatory function,
and its roles in myeloid cell differentiation (23), we speculated
on a functional involvement of IRF4 in the transition of AKI
to CKD. To explore this concept, we assessed cell influx and
fibrosis 5 weeks following unilateral IRI in Irf4-deficient and
wild type (WT) mice. Herein, we aimed to test the following
hypotheses: First, we hypothesized that IRF4, in addition to its
acute anti-inflammatory role, limits the chronic inflammatory
response, residual renal damage, and renal fibrosis. In terms
of potential mechanisms, we studied the influence of IRF4 on
renal macrophage polarization and the local cytokine milieu.
Resulting from both, we hypothesized that renal fibrosis would
occur despite a reduced number of “profibrotic M2 macrophage”
polarization and a Th2 primed adaptive immune response in
these mice. Lastly, we evaluated IRF4 and M1/M2-phenotypic
marker expression in tubular human renal biopsy specimens
with different CKD stages and renal diseases to examine the
transferability of our results to human disease.
MATERIALS AND METHODS
Animal Studies
IRF4-deficient mice (MGI ID: 2387941) (24) in C57BL/6N
background were housed in groups of five mice in pathogen-
free conditions with a 12 h dark/light cycle and unlimited
access to food and water. IRI was performed in 6- to 8-
week old, age-matched WT and gene-deficient female mice.
Contralateral kidneys served as intra-individual controls. All
experimental procedures were performed according to the
German animal care and ethics legislation and had been
approved by the local government authorities. Groups of mice
(n = 8–10) were anesthetized before the left renal pedicles were
clamped for 45min with a microaneurysm clamp via 1 cm flank
incisions (Medicon, Tuttlingen, Germany). Body temperature
was maintained at 35–37◦C throughout the procedure. Mice
were sacrificed 35 days after surgery, and pieces from injured,
contralateral, and sham kidneys were either snap-frozen in
liquid nitrogen or fixed in 4% buffered formalin. In order to
evaluate the systemic cytokine level and the role of IRF4 in the
differentiation of T cells, a single cohort of WT and Irf4−/− mice
were injected with 1 mg/kg of LPS for 12 h. Cl2MDP (clodronate)
was a gift from Roche Diagnostics (Mannheim, Germany) and
incorporated into the liposomes. Mice were injected i.v. with
200 µl clodronate or control liposomes on day −2 before the
IR procedure. This study was carried out in accordance with
the principles of Directive 2010/63/EU on the Protection of
Animals Used for Scientific Purpose and with approval by the
local government authorities, Regierung von Oberbayern or II
LKE in Krakow.
Histological Evaluation
Kidneys were embedded in paraffin, and 2µm sections were
used for periodic acid–Schiff (PAS) stains and fibrosis [scored
by collagen (Sirius red staining) and mouse-anti-smooth muscle
actin (Dako, Denmark, 1:100)]. We evaluated at least three HPFs
from every renal tissue section. Fiber amounts were quantified
based on the percentage of stained area/HPF. Evaluation of the
ratios of the areas of collagen and αSMA fibers to the total area
of the tissue/HPF was performed using Photoshop software. We
categorized fibrosis of every kidney into severity stages (scored
1–5) according to the area ratios of collagen and αSMA fiber
amounts (score 1, 0–5%; score 2, 5–10%; score 3, 10–15%; score
4, 20–25%; score 5, more than 25% of positively stained area)
to obtain the score. For macrophage staining, the following
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TABLE 1 | Gene-specific primers.
Gene name Gene ID Accession nr. Sequence (5′ -> 3′) forward/left Sequence (5′ -> 3′) revers/right
Tnfa ID: 21926 NM_013693 GATCGGTCCCCAAAGGGATG GGTGGTTTGCTACGACGTG
Cxcl2 ID: 20310 NM_009140 CGGTCAAAAAGTTTGCCTTG TCCAGGTCAGTTAGCCTTGC
iNos/Nos2 ID: 18126 NM_010927 TTCTGTGCTGTCCCAGTGAG TGAAGAAAACCCCTTGTGCT
Ifng ID: 15978 NM_008337 ACAGCAAGGCGAAAAAGGAT TGAGCTCATTGAATGCTTGG
Ccl 2 ID: 20296 NM_011333 CCTGCTGTTCACAGTTGCC ATTGGGATCATCTTGCTGGT
Arg 1 ID: 11846 NM_007482 TGAGCTCCAAGCCAAAGTCC GGTCTCTCACGTCATACTCTGTTT
Ym1/Chil3 ID: 12655 NM_009892 AGAAGCAATCCTGAAGACACCAT TTCTATTGGCCTGTCCTTAGCC
Fizz1/Retnla ID: 57262 NM_020509 TGGGATGACTGCTACTGGGT AACGAGTAAGCACAGGCAGT
Il 4 ID: 16189 NM_021283 ATGGATGTGCCAAACGTCCT AGCTTATCGATGAATCCAGGCA
Tgfb 1 ID: 21803 NM_011577 GGAGAGCCCTGGATACCAAC CAACCCAGGTCCTTCCTAAA
Ctgf ID: 14219 NM_010217 AGCTGACCTGGAGGAAAACA CCGCAGAACTTAGCCCTGTA
Mmp 2 ID: 17390 NM_008610 CAAGGATGGACTCCTGGCACAT TACTCGCCATCAGCGTTCCCAT
Mmp 9 ID: 17395 NM_013599 GCTGACTACGATAAGGACGGCA TAGTGGTGCAGGCAGAGTAGGA
Lif ID: 16878 NM_008501 TGAACTTCTGAAAACGGCCT AGCAGCAGTAAGGGCACAAT
Lcn2 ID: 16819 NM_008491 AATGTCACCTCCATCCTGGT ATTTCCCAGAGTGAACTGGC
Ocln ID: 18260 NM_001360536 TGGCAAGCGATCATACCCAGAG CTGCCTGAAGTCATCCACACTC
E-cad/Cdh 1 ID: 12550 NM_009864 GAGGTCTACACCTTCCCGGT AAAAGAAGGCTGTCCTTGGC
Pcna ID: 18538 NM_011045 TGGATAAAGAAGAGGAGGCG GGAGACAGTGGAGTGGCTTT
Fn1 ID: 14268 NM_010233 ACCTCTGCAGACCTACCCAG TTGGTGATGTGTGAAGGCTC
Vim ID: 22352 NM_011701 AAAGCACCCTGCAGTCATTC GCTCCTGGATCTCTTCATCG
Col1a1 ID: 12842 NM_007742 ACATGTTCAGCTTTGTGGACC TAGGCCATTGTGTATGCAGC
Col4a1 ID: 12826 NM_009931 GTCTGGCTTCTGCTGCTCTT CACATTTTCCACAGCCAGAG
Fsp1/S100a4 ID: 20198 NM_011311 CAGCACTTCCTCTCTCTTGG TTTGTGGAAGGTGGACACAA
IP10/Cxcl 10 ID: 15945 NM_021274 TCATCCCTGCGAGCCTATCC GGAGCCCTTTTAGACCTTTTT
Il 12a ID: 16159 NM_001159424 CTAGACAAGGGCATGCTGGT GCTTCTCCCACAGGAGGTTT
Ccr 2 ID: 12772 NM_009915 AGGCATCCATTTTGCTTCTG CAACTCCTTCATCAGGCACA
Irf4 ID: 16364 NM_013674 TGCAAGCTCTTTGACACACA CAAAGCACAGAGTCACCTGG
Zo1/Tjp1 ID: 21872 NM_009386 GTTGGTACGGTGCCCTGAAAGA GCTGACAGGTAGGACAGACGAT
primary antibody was used: rat anti-F4/80 (Serotec, UK, 1:50).
The stained area (% of high-power field stained) was assessed
using Photoshop. At least three random high-power fields per
kidney were assessed and averaged.
RNA Preparation and Real-Time
Quantitative (Taqman) RT-PCR
Reverse transcription and real-time RT-PCR from total RNA
were prepared. The SYBR Green Dye detection system was used
for quantitative real-time PCR on Light Cycler 480 (Roche,
Germany). Gene-specific primers (300 nM, Metabion, Germany)
were used as listed inTable 1. Controls consisting of ddH2Owere
negative for target and housekeeper genes.
Western Blot
Kidneys were manually dissected. One-fifth of the organ
was homogenized on ice in 100 µl buffer [50mM Tris–
HCl, pH 7.5; 150mM NaCl; 100µM sodium orthovanadate,
0.5% sodium deoxycholate, 4% NP-40, 2% Triton X-100;
5mM ethylenediaminetetraacetic acid; 300mM sucrose; protease
inhibitor tablet Complete (Roche, Penzberg, Germany)]. The
lysate was centrifuged for 45min at 30,000 g in 4◦C. Western
blot for IRF4 protein was performed from protein extracts, which
were incubated in two times loading buffer for 5min at 95◦C,
resolved by 10% SDS-PAGE, and transferred to an Immobilon-P
membrane (Millipore, Eschborn, Germany). After blocking with
5% BSA, the filter was incubated with a rabbit polyclonal anti-
IRF4 Ab (1:1,000; Cell Signaling) overnight in TBS. Immune
complexes were visualized using a peroxidase-conjugated anti-
rabbit IgG Ab (1:10,000, Cell Signaling Technology, Beverly,
MA) for 1 h and processed for detection by ECL (Amersham
Pharmacia Biotech Europe, Freiburg, Germany).
In vitro Studies
Spleen monocytes were isolated from C57BL/6N WT mice and
grown on six-well plates in 10% FCS 1% PS RPMI 1,640 medium.
Mouse tubular epithelial cells (TECs) were seeded (5 × 105
cells/ml) in 10% FCS 1% PS K1 medium in six-well plates
and grown to 50% confluence. TECs were isolated according
to an established protocol. In brief, kidneys were mechanically
disrupted, digested, sieved, washed, and plated on cell culture
dished in K1 media. For CD45+, CD11b+, and CD11c+ renal
cell isolation, kidneys were minced, treated with collagenase, and
passed through 70 and 30µm cell strainers; positive selection of
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CD45+, CD11b+, or CD11c+ cells was performed by magnetic
cell sorting technique (MACS separation, Miltenyi, Bergisch-
Gladbach, Germany) according to manufacturer instructions.
After separation, cells were found with a purity of >95% by
flow cytometry analysis. Total RNA and cell culture supernatants
were harvested after 24 h for real-time RT-PCR or ELISAs,
respectively. Cell viability and metabolic activity were assessed
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay according to manufacturer instructions. Mouse
fibroblasts and TECs from WT and IRF4-deficient mice were




Bonemarrow was isolated from the femur and tibia. Erythrocyte-
depleted bone marrow cells were cultured with 20 ng/ml of
M-CSF in RPMI medium supplemented with 10% FCS, 1%
penicillin/streptomycin, 1% non-essential amino acids, and 1%
sodium pyruvate. After 7 days, 0.5 × 106 cells were transferred
to a 12-well plate and stimulated with indicated stimuli−100
LPS and 10 ng/ml IFN-γ (for pro-inflammatory macrophages)
or 25 ng/ml IL-4 and 25 ng/ml IL-13 or 10 ng/ml IL-10 (for M2-
like alternatively activated macrophages)—or left untreated as
media control. All recombinant cytokines were obtained from
ImmunoTools. After 24 h, macrophages were processed for flow
cytometric analysis.
T-Cell Subset FACS
Splenocytes were isolated by pushing the spleen through
a 70µm mesh. After red blood cell lysis, 5 million
splenocytes/ml were seeded in a six-well plate, and cells
were cultured for 5 h in the presence of brefeldin A (1:1,000,
Biolegend), ionomycin (1µg/ml, MilliporeSigma), and PMA
(50 ng/ml, MilliporeSigma).
Flow Cytometry
Intracellular cytokine staining was performed using the BD
Cytofix Cytoperm kit. The following antibodies were used to
characterize the BMM: anti-mouse CD11b BV786, anti-mouse
F4/80 PacificBlue, anti-mouse Arg1 APC, and anti-mouse iNOS
AF488 (all Biolegend, Fell, Germany). T cells were stained with
the following antibodies: anti-mouse CD4 BV605, anti-mouse
CD45 AF700, anti-mouse IFN-γ BV421, and anti-mouse IL-5
PE (all Biolegend). Fixable viability dye efluor780 (ebioscience)
was used in every sample to identify dead cells. Samples were
analyzed on a BD LSRFortessa flow cytometer and FlowJo
v8.7 software.
Patients and Microarray Analysis
Human renal biopsy specimens and Affymetrix microarray
expression data were procured within the framework of the
European Renal cDNA Bank-Kröner-Fresenius Biopsy Bank.
Biopsies were obtained from patients after informed consent
and with approval of the local ethics committees. Following
the renal biopsy, the tissue was transferred to RNase inhibitor
and microdissected into glomeruli and tubulointerstitium.
Total RNA was isolated, reverse transcribed, and amplified.
Fragmentation, hybridization, staining, and imaging were
performed according to the Affymetrix Expression Analysis
Technical Manual (Affymetrix, Santa Clara, CA, USA). CEL
file normalization was performed with the Robust Multichip
Average method using RMAExpress (version 1.0.5) and the
human Entrez-Gene custom CDF annotation from Brain
Array version 18 (http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/genomic_curated_CDF.asp).
To identify differentially expressed genes, the SAM (Significance
Analysis of Microarrays) method was applied using TiGR
(MeV, version 4.8.1). Published gene expression profiles
from patients with different CKDs [cadaveric donor (CD),
tumor nephrectomy (TN), living donor (LD), diabetic
nephropathy (DN), thin basement disease (TMD), minimal
change disease (MCD), hypertensive nephropathy (HTN),
IgA nephropathy (IgA), focal segmental glomerulosclerosis
(FSGS), membranous nephropathy (MGN), LN, and ANCA-
vasculitis (ANCA)] as well as controls (LDs) were used in this
study (CKD data from GSE99340, L; data from GSE32591,
GSE35489, GSE37463). Grouping of the patients into
different CKD stages (CKD 1–5) was done as published in
Shved et al. (25).
Statistical Analysis
Data were expressed as mean ± SEM. Data from WT and
Irf4-deficient mice were compared with ANOVA on ranks,
followed by the Student–Newman–Keuls test using SigmaStat
Software (Jandel Scientific, Erkrath, Germany). Student t-
test was used for direct comparisons between WT and
Irf4-deficient cells/mice in the case of normally distributed
data or sample size n > 15. Mann–Whitney U test was
used in order to analyze data with small sample size and
non-parametric distribution of data. A p <0.05 indicated
statistical significance. Correlation analyses of gene expression
with the estimated glomerular filtration rate (eGFR) were
performed using Spearman correlations [SPSS 25.0 (IBM Corp)].
Bootstrapping was applied to obtain 1,000 times resampling
and derive the corresponding 95% confidence interval for the
correlation coefficient. A p-value below 0.05 was considered to
be statistically significant.
RESULTS
Irf4 Is Sustainably Induced in Macrophages
in vitro and in vivo Following IRI
Replicating and expanding our previous reports (19), we found
IRF4 to be mainly expressed in myeloid cells, with the highest
expression in CD11b+ cells. No mRNA expression under
resting conditions was detectable in TECs from WT mice
(Figure 1A). Likewise, following LPS/TLR4 stimulation, which
is a key signaling event in IRI (26), no Irf4 expression was
detectable from cultured WT-TECs after 6 to 72 h. CD11b+
cells, however, showed solid induction of Irf4, 6 h following
LPS challenge of cultured BMDMs. Only after 24 h, Irf4
expression peaked and remained above baseline level up to
72 h post-stimulation. Thus, compared with other negative
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FIGURE 1 | (A) Shows Irf4 mRNA-relative expression (normalized per 18S rRNA) of wild type (WT) tubular epithelial cells (TECs), differentiated CD11c+ and CD11b+
bone marrow–derived cells under resting conditions. (B) Time course of Irf4 mRNA induction following LPS (100 ng/ml) stimulation in cultured TECs (white) and bone
(Continued)
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FIGURE 1 | marrow–derived myeloid cells (dark gray). (C) Time course of Irf4 mRNA and protein (western blot) expression from whole kidney tissues after induction of
unilateral ischemia reperfusion injury (IRI) up to 5 weeks post-IRI. (D) Irf4 mRNA expression from intrarenal parenchymal cells (white bar, flow-through of magnetic cell
sorting technique (MACS) isolation system), CD11c+ cells (light gray), and CD11b+ (dark gray) bars. *p < 0.05. (E) F4/80-stained macrophages in kidneys of WT 10
days, 3, and 5 weeks post–unilateral IRI induction. The numbers of macrophages were quantitated per HPF; n = 12 per group were examined. Data are shown as
mean ± SEM. **p < 0.01; ***p < 0.001.
regulators of TLR/MyD88 signaling, e.g., A20 (27), Irf4 is slightly
delayed induced but remains expressed for an extended period
(Figure 1B).
Ex vivo, overexpression of Irf4 was detectable from
renal tissue between day 1 and day 5 following unilateral
IRI vs. sham kidneys. Interestingly, Irf4 did not peak
until 5 weeks post-IRI (Figure 1C, left). Similar data
were obtained for IRF4 protein levels using renal protein
extracts 1, 21, and 35 days post-IRI (Figure 1C, right).
Coincident with this finding, numbers of CD45+, CD11c+,
and above all CD11b+ cells were increased in WT-IRI
vs. sham kidneys 3 weeks post-IRI (Figures 1D,E or
data not shown). These data indicate a role for IRF4 in
orchestrating immune-regulatory functions in the chronic
disease phases/healing phase.
IRF4 Does Not Regulate Inflammation, Regeneration,
and Cell Death of TECs
In line with other reports, IRF4 negatively regulates TLR-
mediated inflammation as indicated by cytokine and
chemokine expression in myeloid cells, such as Tnf-α and
Cxcl2, respectively (Supplementary Figures 1A,B). No such
function was observed for non-myeloid TECs. Guo et al.
have demonstrated that IRF4 protects neurons from stroke-
induced cell death (6). In the case of renal ischemia, however,
in accordance with an absence of Irf4 expression in TECs,
no differences in proliferative responses and LPS- or H2O2-
induced cell death were noted between WT and Irf4−/−
TECs (Supplementary Figures 1D,E). Thus, we did not detect
in vitro evidence for potential defects in regenerative properties
of TECs.
Lack of IRF4 Hampers Resolution of the Chronic
Inflammatory Response, Which Is Associated With
Renal Injury and Fibrosis After IRI
Our previous results indicate that IRF4 has a significant
impact on the innate immune responses in myeloid cells
and is involved in regulation of acute responses to injury
[Supplementary Figures 1A,B (19)]. Based on the time course
of Irf4 expression and its role in innate immune signaling,
we hypothesized that IRF4 would also affect chronic renal
inflammation and tissue remodeling. We therefore induced
unilateral renal IRI for 45min in WT and Irf4−/− mice to
assess renal outcome after 5 weeks. Moreover, expression of pro-
inflammatory mediators, e.g., Tnfα, Ifn-γ, IP10, Ccl2, IL-12, and
Ccr2, were elevated in postischemic kidney tissue from Irf4−/−
compared with WT mice (Figure 2A). In contrast to nearly
full recovery of WT kidneys, kidneys of IRF4-deficient mice
displayed loss of kidney weight and compensatory hypertrophy
of the contralateral kidney 5 weeks after acute renal injury
(Figure 2B). This resulted from a loss of tubular cell mass
(Figure 2C), as evidenced by increased density of remaining
glomeruli per HPF (histogram on the right in Figure 2C).
Moreover, α-SMA and Sirius red staining revealed increased
renal fibrosis 5 weeks after IRI in IRF4-deficient animals
compared with C57BL6 WT mice (Figure 2D). Consistently,
we observed significantly increased mRNA expression of
fibrosis markers such as Fsp1, fibronectin, collagen1a,
and Tgf-β in postischemic kidneys of IRF4-deficient mice
(Figure 2E). Moreover, we observed increased mRNA expression
of the kidney damage parameter Ngal as well as relevant
Mmps in postischemic kidneys of IRF4-deficient mice
(Figure 3). Furthermore, several transcripts such as Zo-1,
occludin, and E-cadherin indicating epithelial regeneration
were decreased in renal tissue from IRF4-deficient mice
(Figure 3). Healthy kidneys were not significantly affected
by the genotype (data not shown). Thus, lack of IRF4
aggravates chronic renal inflammation, promotes loss of
TEC mass, and transition to CKD in the long-term outcome
following IRI.
Lack of IRF4 Drives Macrophage Accumulation and
Creates and Promotes a Pro-inflammatory M1
Macrophage Phenotype
Clearly the acute damage induced upon IRI is more severe in
IRF4-deficient animals, which, as previously shown (19), is
due to an exaggerated acute inflammatory response and could
translate into more pronounced chronic damage. On the other
hand, we did not detect hampered TEC-regenerative potential
in vitro (Supplementary Figure 1) and found intrarenal
upregulation of pro-inflammatory mRNA as long as 5 weeks
post-IRI (Figure 2A). We therefore speculated that the chronic
inflammatory response might per se be a distinct and active
process regulated by IRF4 in IRI. As previously shown, acute
hyperinflammation in IRF4−/− mice can be depreciated by
depletion of macrophages using clodronate prior to IRI (19). A
single i.v. injection of clodronate depletes macrophages for <10
days (Supplementary Figure 2). Supporting our hypothesis,
10 days after IRI and clodronate treatment, IRF4-deficient
mice showed higher intrarenal Tnf-α, Ccl2, and iNos mRNA
levels, compared with WT mice, despite a similar level of
inflammation and renal tubular injury during the acute injury
phase (Figure 4A, Supplementary Figures 2B–D). Since Irf4 (a)
is foremost expressed in immune cells, especially macrophages
(Figures 1A–D), and (b) was shown to be an important
mediator of macrophage polarization, we speculated on a
role for macrophages in this chronic inflammatory reaction.
Along with increasing fibrosis and TEC loss, we detected a
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FIGURE 2 | (A) Relative mRNA expression of indicated genes from renal tissues 5 weeks after IRI was normalized per 18S rRNA and normalized to expression levels
of WT mice. (B) Delta kidney weight was calculated as weight of the contralateral non-operated kidney—weight of the kidney that had undergone IRI 5 weeks after
(Continued)
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FIGURE 2 | WT mice (n = 10) and Irf4−/−− mice (n = 8) had undergone unilateral IRI. (C) After 5 weeks, glomerular density was assessed by counting the number of
glomeruli per HPF (n = 8–10 animals per group; each dot represents the average of at least three high-power fields per animal). Remaining tubular mass was
estimated using quantification of tubular cross-sections per HPF [stained with lotus tetragonolobus lectin (LTL)] with image software. N = 8–10 animals per group
(each dot represents the average of at least three high-power fields per animal) were quantified. (D) Renal fibrosis was assessed using smooth muscle actin and Sirius
red stain stains; percentage of positive-stained area was used for calculation (n = 8–10 animals per group were quantitated). (E) Relative mRNA expression of
indicated genes from renal tissues 5 weeks after IRI was normalized per 18S rRNA. mRNA expression of indicated profibrotic genes was determined from kidney
lysates of WT (white bars) and interferon regulatory factor 4 (IRF4)–deficient mice (black bars). Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 3 | Relative mRNA expression of indicated genes from renal tissues 5 weeks after IRI was normalized per 18S rRNA. mRNA expression of indicated genes
was determined from kidney lysates of WT (white bars) and IRF4-deficient mice (black bars). Data are shown as mean ± SEM. *p < 0.05, **p < 0.01.
massive expansion of F4/80-positive macrophages in IRI kidneys
of IRF4-deficient mice, 5 weeks post-induction (Figure 4B),
which appears consistent with increased expression of pro-
inflammatory mediators. IRF4 has been reported to be crucial for
induction of an alternatively activated macrophage phenotype
(M2 phenotype). Consistently, BMDMs from IRF4−/− mice
showed lower expression of M2-phenotypic surface markers
(Arg1 and CD206) when induced with M2 priming of IL-4 and
IL-13 (Figure 4C, left). Of note, IL-10 and ischemic TECs did
not per se induce a strong M2 priming response either in WT or
IRF4-deficient animals. In contrast, we observed unaltered M1
phenotype induction in these mice when cells were stimulated
with LPS and IFN-γ or GM-CSF, which are all known to induce
M1 polarization in vitro (Figure 4C, right). Again, hypoxic
TECs did not significantly foster M1 polarization in any of
the genotypes.
Next, we wanted to assess whether this macrophage
polarization would translate into an altered cytokine milieu
in vivo. M1 macrophages are known to secrete high amounts
of IP10, IL-12, IL-6, and TNF-α, whereas M2 macrophages
primarily secrete Th2 polarizing cytokines such as IL-10 and
IL-4. We therefore challenged IRF4−/− and WT mice with
LPS and assessed systemic cytokine responses from peripheral
plasma. IRF4-deficient mice demonstrated a trend toward
higher IL-6 levels and significantly increased plasma levels
of IL-12, TNF-α, and IFN-γ, suggesting that there might be
a stronger systemic M1 response compared with WT-mice
(Figure 4D). In contrast, there were lower levels for plasma
IL-4 in these mice, potentially indicating a hampered M2-
anti-inflammatory/regenerative response in vivo (Figure 4E).
However, systemic IL-10 levels were again elevated in IRF4-
deficient mice (Figure 4E), which per se did not induce elevated
M2 macrophage marker expression in vitro (data not shown). As
an additional line of evidence, we would further suspect increased
numbers of Th1 vs. Th2 polarized T cells, upon inflammatory
stimuli in IRF4−/− mice due to this M1-prone inflammatory
milieu. In fact, upon injection with LPS, we detected increased
numbers of IFN-γ-producing, yet lower numbers of IL-4− or IL-
5− secreting, CD3+CD4+ positive peripheral cells, in accordance
with a skewed Th1/Th2 cell ratio (Figures 4F,G). Taken together,
IRF4 deficiency promotes anM1macrophage–predominant pro-
inflammatory signature upon TLR activation in vivo, which
should also apply to intrarenal macrophages post-IRI.
To test this, we isolated CD11b+ cells from kidneys of
WT and IRF4−/− mice, 3 weeks after induction of unilateral
IRI. Macrophages from IRF4−/− kidneys showed predominant
expression ofM1-phenotypic transcripts such as Tnf-α, iNos, Ifn-
γ, and Ccl2 (Figure 5A). In line with this, we found reduced
expression of M2-phenotypic transcripts, namely Arg1, Ym1,
Fizz1, and Il4 (Figure 5B), in these cells. Thus, not only do IRF4-
deficient mice show impaired M1 polarization in vitro; they also
demonstrate reduced M2 macrophage polarization in injured
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FIGURE 4 | (A) Wild type and IRF4-deficient mice underwent unilateral IR after having received an i.v. injection of control liposomes or clodronate that depletes
macrophages and DCs. Clodronate treatment prevented renal inflammation seen in untreated IRF4-deficient mice and evidenced by intrarenal expression of
(Continued)
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FIGURE 4 | pro-inflammatory mediators. Data are expressed as mean of the ratio vs. the respective 18s rRNA level ± SEM. *p < 0.05 vs. wild type. (B) Sections of
kidneys of WT and Irf4−/− mice were stained for F4/80, 5 weeks after unilateral IRI. Number of infiltrating macrophages was assessed as stained area per HPF (n =
8–10 animals per group; each dot represents the average of at least three high-power fields per animal). (B,C) BMDMs from WT and Irf4−/− mice were cultured and
stimulated with IL-4 and IL-13 as M2 differentiating agents, or LPS + IFN-γ for M1 differentiation. Flow cytometric analysis was performed for M2 (Arg1+) and M1
(iNOS+) CD11b+ and F4/80+ cells. (D,E) Mice were injected with LPS. Mice were euthanized after 12 h to obtain plasma samples for determination of the indicated
cytokines. (F,G) Flow cytometry of spleen T-cell populations was performed from WT and Irf4−/− mice under normal conditions and 12 h after injection of LPS.
Intracellular staining for IFN-γ or IL-5, respectively, was used to differentiate Th1 and Th2 type T-cell responses. *p < 0.05, ***p < 0.001; **p < 0.01.
FIGURE 5 | Unilateral IRI was induced in 4- to 6-week-old WT (white bars) and IRF4-deficient mice (black bars). Operated kidneys were harvested 21 days after
induction of the model. CD11b+ cells were isolated from kidneys by MACS magnetic separation. Cells were checked for purity and lysed for RNA extraction. RT-PCR
of the indicated genes was performed and normalized per 18S rRNA. *p < 0.05.
kidneys in vivo. Therefore, in the absence of IRF4, the abnormal
infiltrates of macrophages in the chronic inflammatory phase
following IRI are mostly pro-inflammatory M1-primed. This
might explain why IRF4-deficient mice fail to resolve intrarenal
inflammation properly and thus develop progressive TEC loss
and fibrosis.
Gene Expression Analysis of IRF4 and Selected
Macrophage Polarity Genes in Patients With Different
Renal Diseases and Across Different CKD Stages
In order to estimate the transferability of our results to
human renal disease, we assessed transcriptional levels of
IRF4 and transcripts encoded by selected macrophage polarity
genes in glomeruli and tubular compartments from biopsies
of individuals with different CKD stages (Figure 6 and
Supplementary Figure 3) vs. LD biopsy specimens. Herein,
IRF4 was not differently expressed across CKD stages 1–
5 vs. LD in tubular compartments (Figure 6A). However, a
progressive M2 macrophage polarization signature was evident
across CKD stages 1–5 vs. LD, as shown by low transcript
levels of CHI3L1, a pro-inflammatory molecule, and reduced
levels of NOS2, yet a higher expression of mediators secreted
by M2 macrophages, TGF-β1, or CCR-2 (Figure 6A). Despite
downregulation of “classical M1 macrophage” markers, we still
noted overexpression of inflammatorymediators usually secreted
by M1, such as CXCL10 and CCL2, in terms of a “residual M1
functionality.” Glomerular gene expression data can be retrieved
from Supplementary Figure 3A. These data clearly indicate a
general compartment dysregulation of macrophage polarity gene
transcripts toward an M2 polarized signature in human CKD.
In this initial approach, differential regulation of IRF4 and
a residual non-resolving M1 signature might have been missed
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FIGURE 6 | Gene expression analysis of IRF4 and selected macrophage polarity genes in tubulointerstitium of manually microdissected biopsies from patients with
different CKD stages (A) and renal diseases (B). Values are expressed as log2-fold change compared to controls (living donors, LDs). All represented genes are
significantly changed (q < 0.05) and non-significantly changed genes denoted as ns. Chronic kidney disease 1 (CKD1): n = 56; CKD2: n = 46; CKD3: n = 37; CKD4:
n = 26; CKD5: n = 10; living donor (LD): n = 42; hypertensive nephropathy (HT): n = 21; lupus nephritis (LN): n = 32; minimal change disease (MCD): n = 15.
due to heterogenicity of CKD causes. We therefore analyzed the
regulation of IRF4 and selected macrophage polarity genes in
patients with hypertensive nephropathy (HT), which, according
to our understanding, comes closest to chronic/postischemic
kidney injury. Additionally, we analyzed patients with LN
and MCD. LN specimens served as a model for intrarenal
inflammation known to also affect the tubular system and,
MCD was used as non-fibrotic disease control. In fact, HT
specimens, similar to LN specimens, showed a predominantly
M2 macrophage–prone expression signature. However, HT
patients showed a mild but significant upregulation of CCL2
and CXCL10 (28–31), chemokines released by or attracting
M1 macrophages during inflammation, compared with LD
and LN patients (Figure 6B). In addition, NOS2 was not
altered in HT (Figure 6B), whereas a marked downregulation
was noted amongst LN patients (Figure 6B). Thus, a non-
resolving M1 signature might be present in HT patients, despite
parallel overexpression of M2 regulatory genes. The fact that
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TNFα mRNA was not elevated in HT vs. LD specimens
indicates the absence of an acute postischemic inflammatory
response (Figure 6B). Glomerular gene expression profiles of
patients with HT, LN, and MCD can be retrieved from
Supplementary Figure 3B. To analyze whether differences in
IRF4 expression correlate with CKD progression in HT or LN,
a correlation analysis was performed. However, neither in HT
nor in LN patients, a significant relationship between IRF4 gene
expression and eGFR in glomeruli or the tubular system could be
observed (data not shown).
DISCUSSION
IRF4 is a suppressor of innate immune signaling, by inhibiting
TLR/MyD88 signaling (32). The relevance of this inhibitory
function is underscored by enhanced susceptibility to septic
shock in mice and an autoinflammatory immune-defective
disease in IRF4-defective inherited humans (32, 33). Likewise,
in the acute phase of IRI, IRF4 acts as an endogenous regulator
of myeloid cell activation, i.e., dendritic cells, suppresses TNF-α
release from intrarenal myeloid cells, and thereby limits tubular
cell necrosis, tissue inflammation, and acute renal failure 24 h and
5 days post-IRI (19).
The focus of this project was on the long-term regulatory
function of IRF4 post-IRI. Our data reveal that IRF4 suppresses
the progression to renal fibrosis and CKD 3–5 weeks following
IRI in mice, which is the essential end point for those recovering
from acute renal failure. Since IRF4 limits the acute damage in
AKI, this might not be surprising at first glance, and some of
the damage observed is certainly due to an exaggerated acute
damage response. Still, the resolution of acute renal inflammation
after the injury is not a solely passive process depending on the
acute inflammatory response, but in part an active and controlled
process. Initial inflammation does not necessarily correlate with
the extent of fibrosis and CKD thereafter (34–36). For example,
SIGIRR, a negative regulator of TLR4/MyD88 signaling, which
significantly reduces intrarenal Cxcl2/Mip2 expression, leukocyte
interstitial transmigration, and TEC necrosis following IRI, did
not affect fibrosis induction in a UUO model (35, 36). Vice
versa, the immune modulatory molecule IRAK-M showed no
impact on acute interstitial inflammation 24 h after IRI, yet
IRAK-M protects from fibrosis induction 5 weeks after (34).
Yet, IRF4 and these negative regulators possess different and
distinct signaling ability, and these observations should therefore
not be extrapolated. Interestingly, clodronate-treated Irf4−/−
mice displayed increased intrarenal pro-inflammatory mRNA
expression in the late phase following IRI despite a normalized
initial inflammatory response. The data potentially indicate
that similar to IRAK-M, IRF4 is an important mediator to
restore renal tissue homeostasis following ischemia reperfusion
in mice—in addition to its known ability to dampen the acute
inflammatory response. In accordance, Irf4 peak expression
in renal tissue was shifted to the chronic phase following
IRI. Likewise, in murine stroke models, where IRF4 promotes
neuronal survival, Irf4 expression did not peak until 72 h after
ischemia induction (6). Consequently, Irf4−/− mice displayed
upregulation of pro-inflammatory mRNA, and kidney interstitial
macrophage infiltrates 5 weeks post-IRI, demonstrating a non-
resolving inflammatory response.
Together these data could point toward a role for IRF4
in controlling chronic inflammation and tissue repair in the
post-injury phase. Supporting this concept, in TNBS-induced
colitis, IRF4 is required for (acute) colitis induction but
suppresses chronic inflammation in the chronic disease phase (7).
But what could be the mechanistic role of IRF4? Postischemic
Irf4−/− kidneys demonstrated significantly increased chronic
tissue inflammation. In our case, macrophages were the
predominant cell type inside the inflamed kidneys.
A variety of functions have been reported for IRF4. IRF4 is
important for macrophage polarization toward an alternatively
activated/M2 phenotype, which can resolve inflammation but
may promote tissue fibrosis (37). In adaptive immunity or
under chronic inflammatory conditions, IRF4 is further required
for differentiation of Th2 effector functions, Treg and Th17
differentiation (9, 10, 38). In addition, profound alterations
in systemic cytokine responses have been reported for IRF4-
deficient mice, such as reduced secretion of Th2 cytokines, IL-
17, and IL-21 by T cells (10–12, 39). Upon injection with LPS,
Irf4−/− mice demonstrated marked overproduction of IL-12,
TNF-α, IFN-γ, and IL-10, yet we noted lower systemic IL-4
levels. This came along with a predominant systemic Th1 vs.
Th2 response, as demonstrated by lower numbers of IL-5+ and
higher numbers of IFN-γ+ Th cells. We further demonstrate
a similar ability of Irf4−/− mice to generate classically “pro-
inflammatory/M1” macrophages, when stimulated with M1
polarizing agents, such as LPS and IFN-γ. However, as shown
for helminth infections and in anti-tumor responses (18, 40),
Irf4−/− mice showed hampered M2 macrophage polarization,
when stimulated with IL-4 and IL-13 ex vivo. We found that IL-
10, which was upregulated in Irf4−/− mice upon LPS challenge,
was not a strong inducer of M2 responses in either WT or
IRF4-deficient mice. Likely, as a combined effect of (a) M2
polarization defects of Irf4−/− macrophages and (b) a rather
M1-priming systemic cytokine milieu, we detected foremost M1-
primed macrophages in chronically inflamed kidneys of Irf4−/−
mice. Predominance of M1 polarized macrophages came along
with chronic inflammation, loss of tubular epithelial mass, renal
fibrosis, and scaring in Irf4−/− mice 5 weeks post-IRI. Certainly,
the fundamental proof for a causative role of IRF4-deficient
M1-primed macrophages in the chronic inflammatory phase
of renal disease could be answered using conditional and cell-
specific knock-out mice. Nevertheless, based on (a) the well-
documented expression of IRF4 particularly in immune cells,
(b) renal hyperinflammation 5 weeks post-IRI besides tissue-
infiltrating M1-primed macrophages, and (c) the occurrence
of intrarenal hyperinflammation in Irf4−/− mice despite a
clodronate depletion of macrophages in the acute phase of
the injury, we consider that M1 macrophage–driven chronic
renal inflammation causes CKD in our murine model. In
this respect, our associative data are in line with reports by
others showing exaggerated disease progression after adoptive
transfer of M1 polarized macrophages into adriamycin-induced
chronic nephropathy (41). In contrast to ischemic brain injury
models (6), we did not detect any direct impact of IRF4
on the stress resistance or proliferative response of renal
Frontiers in Immunology | www.frontiersin.org 12 October 2019 | Volume 10 | Article 2162
Lorenz et al. Role of IRF4 in CKD
TECs. Still, Lee et al. in an elegant approach have shown
inhibition of TEC regeneration by M1 macrophages in vivo, a
mechanism that could additionally contribute to the observed
phenotype (42).
In accordance with this, we found hints of a resident M1
chemokine signature in tubular dissected renal biopsy specimens
from human HT patients. These results indicate a potential
functional role for IRF4/a non-resolving M1 signature in human
postischemic kidney disease. However, the models used do not
match perfectly, and the rather minimal dysregulation of IRF4
points toward additional, more relevant regulators of chronic
inflammation in postischemic kidney disease. It should be noted
that across later CKD (III–V) stages and in HT patients vs. LD,
TGFβ1 was found overexpressed, in line with its reported role as
a key profibrotic and anti-inflammatory cytokine in CKD and a
regulator of tubular damage in ischemic injury (43). Based on our
data, however, with no TGFβ dysregulation in CKD stages I and
II, we consider dysregulated TGFβ1/Smad signaling across the
latter event. The demand for further human studies is reasonable
in this respect.
Still, our murine data challenge the concept that alternatively
activatedmacrophages are essential for fibrosis induction in CKD
(37). In Irf4−/− mice, the maintenance of an M1-primed pro-
inflammatory milieu was associated with kidney fibrosis and
CKD progression. Furthermore, our data clearly contradict the
concept that a Th1 > Th2 primed adaptive immune response
can per se be considered protective (44), as IRF4-deficient mice
showed a clear Th1 signature yet developed massive renal fibrosis
following AKI. Lastly, these data highlight the importance of
IRF4 as negative regulator not only of the acute inflammatory
response, but foremost as a mechanism to tune down the chronic
inflammatory tissue response. It is tempting to speculate that
since Irf4−/− mice are unable to form proper M2 responses,
they are unable to resolve intrarenal chronic inflammation. Our
data further indicate that this is exerted not only by intrinsically
alteringmacrophage polarization but also by altering the systemic
cytokine milieu, which could secondarily affect the macrophage
phenotype. However, further studies are needed to unravel this
complex network.
In summary, IRF4 acts as an important regulator of CKD after
AKI in mice. A more detailed understanding of IRF4 function in
the context of human CKD is needed to estimate its value as a
potential therapeutic target.
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